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INTRODUCTION
The diagnosis of Aspergillus species has been a major chal-
lenge in the management of patients with invasive aspergillo-
sis (IA). Although early detection is critical in clinical deci-
sion making, conventional blood culture rarely detects Asper-
gillus species (1-3). Therefore, we should rely on nonculture-
based methods for the diagnosis of IA.
Several molecular detection methods have been devised
(2). Of these, the detection of galactomannan by enzyme im-
munosorbent assay (GM-EIA) is one of the standard mea-
sures (4-6) and was included as an important component of
microbiological factors in the diagnostic criteria devised by
the Mycology Study Group of the European Organization
for Research and Treatment of Cancer (EORTC/MSG) (7).
In addition to this, we have used nucleic acid sequence-based
amplification (NASBA) as a nucleic acid detection method.
NASBA is an isothermal amplification process to detect
mRNA by hybridization using electrochemiluminescent
(ECL) probes (8). With this method, we have reported the
cutoff NASBA index value for clinical diagnosis and suggest-
ed its usefulness for monitoring and management of clinical
course of invasive aspergillosis for the first time (9). 
Recently, this technique adopts real-time scheme (RTi-
NASBA) by combining with molecular beacon probes (10).
It has been applied to the diagnosis of various pathogens such
as HIV (11, 12), hepatitis B virus (13), influenza virus (14),
etc., but there has been only one preliminary report on the
detection of Aspergillus species so far (15).
In this study, we have compared RTi-NASBA with conven-
tional NASBA and GM-EIA for the diagnosis of IA. To our
knowledge, this is the first comparative study of RTi-NASBA
for the detection of Aspergillus species. 
MATERIALS AND METHODS
Patients
We performed this study from May 2004 to May 2005 in
the Catholic hematopoietic stem cell transplantation (HSCT)
center affiliated to The Catholic University of Korea, College
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Comparison of the Real-time Nucleic Acid Sequence-based 
Amplification (RTi-NASBA) with Conventional NASBA, and 
Galactomannan Assay for the Diagnosis of Invasive Aspergillosis
We compared a real time-nucleic acid sequence-based amplification (RTi-NASBA)
with conventional NASBA, galactomannan enzyme immunosorbent assay (GM-
EIA), and Mycology Study Group of the European Organization for Research and
Treatment of Cancer (EORTC/MSG) criteria for the diagnosis of invasive aspergillo-
sis (IA). From May 2004 to May 2005, blood samples (314 in total) were collected
twice a week from 78 patients with hematologic diseases during neutropenic fever
after chemotherapy or hematopoietic stem cell transplantation. Results were com-
pared with each other on the basis of EORTC/ MSG criteria. The cutoff of conven-
tional NASBA was set to be 3.5; GM 0.5; RTi-NASBA, 20% above the negative con-
trol. There were 22 patients with IA (7 probables and 15 possibles) and 56 patients
with nonfungal infection. The Kappa statistic for RTi-NASBA versus conventional
NASBA was 0.80 (0.66-0.82; p<0.001) indicating that there was fairly good accor-
dance between two tests. RTi-NASBA showed sensitivity 0.96, specificity 0.43,
positive- and negative-predictive value 0.40 and 0.96, respectively. GM showed
good specificity (0.98), while the sensitivity (0.45) was poor. When we use the com-
bination of GM with either of two NASBAs, the sensitivity was improved up to 100%.
In conclusion, RTi-NASBA could be a good alternative to the conventional one for
the screening of IA.
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of Medicine. Febrile neutropenic patients unresponsive to
broad-spectrum antibiotics by 72 to 96 hr of initiation were
enrolled consecutively into the study. Blood samples were
usually obtained twice a week until recovery from neutrope-
nia. IA was diagnosed on the basis of the standard definitions
of invasive fungal infections using the EORTC/MSG crite-
ria (10). Using these definitions, we classified the study pop-
ulation into four probability levels: proven, probable and
possible IA, and non-fungal infection (NFI).
NASBA
NASBA was performed in accordance with the scheme
we used in the previous study (9). In brief, RNA was extract-
ed from an EDTA-treated whole blood sample using Nu-
cliSens Isolation Reagents (BioMerieux Korea & Diagenex,
Seoul, Korea) and QIAGEN RNeasy Minikit (Quiagen,
Germany). Then we performed NASBA with a NucliSens
kit and an electrochemiluminescence (ECL) detector (Bio-
Merieux Korea & Diagenex, Seoul, Korea) according to the
manufacturer’s instructions. Primers and capture probes for
detecting Aspergillus species were made using the scheme
proposed by Loeffler et al. (16). The sequence of primer 1
(including the T7-promoter region) was:
5′ -AATTCTAATACGACTCACTATAGGGGAGCAA-
AGGCCTGCTTTGAACA-3′ , and that of primer 2 (includ-
ing ECL-tail) was:
5′ -GATGCAAGGTCGCATATGAGGCCGCGGTAAT-
TCCAGCTCCAATA-3′ .
The capture probe sequence, which binds to clinically rel-
evant Aspergillus species, was 5′ -GGTCCGCCTCACCGC-
GAGTACTG-3′ . Results are expressed as ECL counts. The
wild type (WT) signal value in each experiment was set at
0.01×the signal from the ruthenium-labeled paramagnetic
beads as reference solution. Every NASBA index was calcu-
lated as the ratio: (measured ECL count of NASBA)/(WT
signal value). 
The initial value of the NASBA index of every patient was
included in the calculation. The cutoff value of the NASBA
index was determined by using receiver-operating character-
istic (ROC) analysis. Sensitivity and specificity were calculated
using cases of IA on the basis of EORTC/MSG criteria as a
gold standard.
RTi-NASBA 
The primer 1 & 2 were same as those for conventional NA-
SBA. The molecular beacon was labeled with 6-carboxyflu-
orescein (6-FAM) at its 5′ -end and quencher DABCYL at its
3′ -end. The sequence was 5′ -(FAM) CGA TCG GGT CCG
CCT CAC CGC GAG TAC TGC GAT CG-DABCYL-3′ .
RTi-NASBA was performed using NucliSens EasyQ incu-
bator and detection system (BioMerieux Korea & Diagenex,
Seoul, Korea) according to the manufacturer’s instruction. 
Threshold level of RTi-NASBA was determined according
to the manufacturer’s instruction. To determine the baseline
fluorescence (BF), a random sampling of 20 specimens from
healthy volunteers were analysed in four different runs using
the NucliSens EasyQ Analyzer. The threshold level with real-
time detection was calculated by multiplying the average
baseline fluorescence (BFmean) resulting from a random sam-
pling with the ratio (BFratio), as described in the following
equation: Threshold level=BFmean×BFratio where BFratio equals
to BFhighest divided by BFlowest. In this experiment, we obtained
the average threshold value as 1.20 by multiplying the BF
value of 1.11 with the BF ratio of 1.07, which was approxi-
mately 20% above the value of negative control. 
The scheme of RTi-NASBA is illustrated in Fig. 1. 
GM-EIA 
Serum GM was measured by sandwich ELISA using rat
monoclonal antibody EB-A2 (Platelia Aspergillus, Bio-Rad
Korea). Results are expressed as the ratio of the optical den-
sity of the sample to that of a standard sample containing 1
ng of GM/mL. A GM index of ≥0.5 in at least two consec-
utive samples was regarded as positive.
Comparison with conventional NASBA (NASBA-ECL)
and GM-EIA
The result of RTi-NASBA was compared with those of
NASBA-ECL and GM-EIA on the basis of EORTC/MSG
criteria. We also assessed the combination of GM-EIA and
NASBA-ECL or RTi-NASBA for the diagnostic yield of IA.
Concordance of methods was measured using Kappa statis-
tics.
Fig. 1. Scheme of real time-nucleic acid sequence-based amplifi-
cation (RTi-NASBA); upper: Sequence of RTi-NASBA; lower left:
structure of molecular beacon and the process of detection by
emission of fluorescence from R (recipient) on receiving light and
freed from the inhibitory action of Q (quencher); lower right: a sam-
ple of the result from RTi-NASBA.
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Single step procedure of combining amplification of RNA and
simultaneous detection by molecular beacon (see below) in
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RESULTS
Characteristics of the study population 
A total of 314 samples were obtained from 22 patients
with IA (7 probables and 15 possibles) and 56 patients with
NFI. 
The male-to-female ratio was 10:12. Most cases were pre-
sented with pneumonia (n=13), but there were one case of
sinusitis, and eight cases were presented with intractable
fever. Thirteen (59.1%) of the cases were diagnosed with
acute myelocytic leukemia, and 5 with acute lymphocytic
leukemia. There were also one case of chronic myelocytic
leukemia and one myelodysplastic syndrome. All but one
case received cytotoxic chemotherapy. The mortality was
23% (5/22). 
Calculating the cutoff value of NASBA-ECL
Using probable and possible cases as a gold standard, the
area under the ROC curve (AUC) was 0.937±0.02 (95%
confidence interval. 0.902-0.972; p<0.001). The optimal in-
flection point was located between NASBA index 3.105 (sen-
sitivity 0.91, specificity 0.68) and 3.559 (sensitivity 0.91, spe-
cificity 0.77), as illustrated in Fig. 2. On the basis of this anal-
ysis, we decided the cutoff value of NASBA-ECL to be 3.5. 
Sensitivity and specificity of NASBA-ECL, RTi-NASBA,
and GM-EIA
The sensitivity of NASBA-ECL (3.5 as a cutoff point) was
high (0.95) at the expense of low specificity (0.45). Positive
and negative predictive values were 0.40 and 0.96, respectively
(Table 1).
The sensitivity and specificity of RTi-NASBA showed a
profile similar to NASBA-ECL: high sensitivity and negative
predictive value (0.96 each) in contrast to low specificity and
positive predictive value (0.43 and 0.40, respectively). 
The sensitivity of GM-EIA (0.5 as a cutoff point) was rather
low (0.45), while the specificity was high (0.98). Positive and
negative predictive values were 0.91 and 0.82, respectively. 
As depicted in Table 2, the agreement between two NA-
SBA methods was fairly good with kappa statistics of 0.80
(95% confidence interval: 0.66-0.82, p<0.01). 
Enhancement of diagnostic yield by combining the results
of GM-EIA and NASBA
When either of GM-EIA index ≥0.5 or NASBA-ECL
≥3.5 were used as positive cutoff values, the diagnostic yield
NASBA, nucleic acid sequence-based amplification; NFI, non-fungal
infection.
Proba-
ble
Possi-
ble
NFI sn sp ppv npv
NASBA
<3.5 0 1 25 0.95 0.45 0.40 0.96
≥3.5 7 14 31
RTi-NASBA
Negative 1 0 24 0.96 0.43 0.40 0.96
Positive 6 15 32
GM-EIA
<0.5 2 10 55 0.45 0.98 0.91 0.82
≥0.5 5 5 1
Table 1. Sensitivity (sn), specificity (sp), positive- and negative-
predictive value (ppv and npv) of NASBA, real time (RTi)-NASBA,
and galactomannan enzyme immunosorbent assay (GM-EIA)
Kappa statistics: 0.80 (0.66-0.82; p<0.01).
NASBA, nucleic acid sequence-based amplification; RTi-NASBA, Real-
time NASBA.
RTi-NASBA NASBA≥3.5 NASBA <3.5 Total
Positive 48 5 53
Negative 4 21 25
Total 52 26 78
Table 2. The agreement between NASBA and RTi-NASBA
IA NFI sn sp ppv npv
If either GM ≥0.5 or NASBA ≥3.5 22 32 1.0 0.43 0.41 0.97
If not 0 24
If either GM ≥0.5 or (+) RTi-NASBA 22 33 1.0 0.41 0.41 0.97
If not 0 23
Table 3. Combination of GM-EIA with NASBA or RTi-NASBA for
enhancing the diagnostic yield of invasive aspergillosis (IA) and
non-fungal infection (NFI)
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Fig. 2. Receiver-operating characteristic (ROC) curve and a table
of statistics for selected thresholds for the cutoff NASBA value on
the group of patients with probable and possible invasive asper-
gillosis as a standard (AUC: area under the ROC curve, 95% C.I.:
95% confidence interval). 
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BA vity ficity
2.275 0.955 0.553
2.312 0.955 0.557
2.346 0.939 0.557
2.805 0.939 0.629
2.822 0.924 0.636
3.055 0.924 0.674
3.105 0.909 0.677
3.559 0.909 0.777
3.574 0.894 0.777
GM-EIA, galactomannan enzyme immunosorbent assay; NASBA, nu-
cleic acid sequence-based amplification; RTi-NASBA, Real-time NASBA;
sn, sensitivity; sp, specificity; ppv, positive predicitve value; npv, nega-
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of IA was enhanced with sensitivity up to 100%. The diag-
nostic power was also enhanced when either of GM-EIA in-
dex or RTi-NASBA was used as positive markers: the sensi-
tivity also rose up to 100% (Table 3). 
DISCUSSION
In addition to GM-EIA, various diagnostic measures based
on the molecular detection have been developed so far (1-3).
Among them, we used the amplification and detection of
mRNA from Aspergillus (NASBA) and applied the method
to patients with febrile neutropenia for the enhancement of
diagnostic yield and establishment of treatment guideline
as reported in our previous report (9), which was meaningful
on the aspect of the first presentation of practical guideline for
the clinical decision making.
In this study, we evaluated the RTi-NASBA as an alterna-
tive to the conventional NASBA. RTi-NASBA is reported
to be advantageous over conventional one in many ways; the
amplification and detection are performed in one tube and
thus RTi-NASBA has fewer steps prior to amplification, no
post-amplification hybridization, less time-consuming, and
lower chance of amplicon contamination (17). It is also easier
to perform and quantify. Although these differences are not
significant between these two NASBA methods, we thought
these advantages could outweigh the slightly higher reagent
cost. In our study, the interface of RTi-NASBA was user-frien-
dly, easy to perform, and less laborious than conventional
NASBA. Time-saving was about 30 min; 3 hr in RTi-NA-
SBA vs. 3.5 hr in NASBA on average.
The good measure of agreement (kappa value=0.8) sug-
gested that RTi-NASBA could be a comparable to the con-
ventional one with respect to the diagnostic power.
RTi-NASBA as well as conventional NASBA (NASBA-
ECL) showed an excellent sensitivity and negative predictive
value with poor specificity and positive predictive value, while
GM-EIA showed opposite performance (good specificity with
poor sensitivity). 
Though it is enrolled as a formal component of diagnostic
criteria in EORTC/MSG, the low sensitivity of GM-EIA lim-
its its value as a screening measure (18). Therefore, the diag-
nostic yield of GM-EIA should be complemented by another
method, and conventional- or RTi-NASBA could be the one
as suggested in our previous report. However, the capability
of these two NASBA methods could be questioned because
of low specificity in this study. This can be interpreted in
many ways. Which method you will prefer depends on which
goal you want from the detection method: an accurate diag-
nosis or screening as many as possible. As the main objec-
tive of nonculture-based detection of IA is a screening for
the clinical decision making rather than accurate diagnosis,
higher sensitivity at the expense of specificity would be more
important.
The choice of optimal cutoff value depends on the purpose
of the test. As the main objective of this study was to evalu-
ate the test for initial screening of patients with a risk of IA,
we chose a value of the NASBA index giving an appropri-
ately high sensitivity and an acceptably low false positive rate
(1-specificity).
The diagnostic yield could be enhanced by combination
of GM-EIA with either of conventional- or RTi-NASBA. In
our study, combination of GM with either of two NASBA
methods yielded the sensitivity of 100%.
Our study has some limitations. We did not include pro-
ven cases in this study. Adding the probable and possible
cases without proven cases to the gold standard might have
influenced the validation of our tests. Practically, obtaining
a specimen for confirmation is much more difficult in almost
all clinical settings because of the inability to perform tissue
biopsies and autopsies owing to immunocompromised sta-
tus as well as refusal of patients and families. However, we
think that the high stringency of EORTC/MSG criteria for
probable and possible cases could specifically select invasive
fungal diseases with a very high index of suspicion. In spite
of all these drawbacks, this study could offer us the validity
of two NASBAs as adequate screening tools.
In summary, RTi-NASBA could be a good alternative to
the conventional NASBA using the ECL detection system. If
either the GM-EIA or NASBA (conventional- or RTi-NAS-
BA) suggests IA, it could provide a valid clue to the initia-
tion of antifungal treatment before obtaining confirmatory
test results.
Adding these diagnostic markers for fungal disease to the
treatment strategies could be also beneficial. For this purpose,
further studies are underway to set up the quantitative mea-
surement of RTi-NASBA using internal calibrator RNA as
a control and to establish the basis of pre-emptive antifungal
treatment guided by these molecular diagnostic markers.
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